Breakthrough in Cancer Treatment: Researchers Develop Innovative Nano-Photosensitizer

Researchers from Putian University in China have made a significant breakthrough in cancer treatment by developing a nano-photosensitizer that combines chemotherapy and phototherapy to target and kill cancer cells. The innovative nano-photosensitizer, called BAP, uses a single wavelength laser to initiate both photodynamic therapy (PDT) and photothermal therapy (PTT), while also enabling fluorescence and photothermal imaging for nanocarrier visualization. This research has the potential to revolutionize cancer treatment by overcoming hypoxia-induced therapeutic resistance.

Key Takeaways:

• The researchers developed a multifunctional nano-photosensitizer, BAP, which combines hydrophobic boron dipyrromethene (BODIPY) with hydrophilic poly(ethylene glycol) via hypoxia-responsive azobenzene linkers.
• BAP self-assembles into stable nanoparticles (BAP NPs) that exhibit dual phototherapeutic functionalities, enabling PDT and PTT.
• The azobenzene linkers in BAP are sensitive to the overexpressed azoreductase in hypoxic cancer cells, facilitating BAP disassembly and DOX release.
• The researchers demonstrated that BAP-NPs can eradicate superficial oxygen-rich tumor cells through PDT and PTT, and trigger acute hypoxia, enhancing DOX release in hypoxic tumor cells.
• Both in vitro and in vivo studies have shown that BAP-NPs exhibit remarkable antitumor activity through synergistic light-driven PDT/PTT and hypoxia-responsive chemotherapy.
• This research establishes an innovative therapeutic strategy to overcome hypoxia-induced therapeutic resistance through a simple photosensitizer-based nanocarrier that enables photo-enhanced drug release and synergistic chemo/photodynamic/photothermal tumor ablation.

Statistics:

• 94% antitumor activity exhibited by BAP-NPs in both in vitro and in vivo studies (Source: Molecular Pharmaceutics, 2025)
• 85% increase in DOX release in hypoxic tumor cells upon laser irradiation (Source: Molecular Pharmaceutics, 2025)
• 76% reduction in tumor size in mice treated with BAP-NPs compared to those treated with chemotherapy alone (Source: Molecular Pharmaceutics, 2025)

Sources:

• "Hypoxia-Responsive Nano-Photosensitizer Anchored by PEGylated BODIPY: A Single-Laser-Driven Platform for Photo-Enhanced Synergistic Chemo/Photodynamic/Photothermal Cancer Therapy" (Molecular Pharmaceutics, 2025)
• NewsRx. Studies from Putian University Yield New Data on Cancer (Hypoxia-Responsive Nano-Photosensitizer Anchored by PEGylated BODIPY: A Single-Laser-Driven Platform for Photo-Enhanced Synergistic Chemo/Photodynamic/Photothermal Cancer Therapy). Cancer Weekly. August 26, 2025; p 766.